# DOAC’s verlagen beroerte- en sterfterisico bij atriumfibrilleren met eerdere hersenbloeding — geen verhoogd bloedingrisico

*geplaatst 2026-10-30 · Atriumfibrilleren · Neurology · doi 10.1212/WNL.0000000000218719 · https://hartvaat.nl/2026/11/24/doacs-verlagen-beroerte-en-sterfterisico-bij-atriumfibrilleren-met-eerdere-herse/*

In een Finse cohortstudie onder 1.502 patiënten met atriumfibrilleren en een eerdere intracraniale bloeding daalde het 1-jaars risico op ischemische beroerte van 4,1% (geen anticoagulatie) naar 0,7% bij DOAC-gebruik (HR 0,17), zonder verhoogd risico op hersenbloeding. Warfarine verlaagde eveneens beroerte- en sterfterisico, maar ging wel gepaard met een hoger bloedingrisico (HR 1,85), tenzij de TTR ≥70% was. Deze bevindingen ondersteunen DOAC’s als eerste keuze bij deze kwetsbare groep en benadrukken het belang van individuele afweging tussen beroerte- en bloedingrisico.

## English: Anticoagulation in Atrial Fibrillation With Previous Intracranial Bleeding: Competing Adverse Events in a Nationwide Cohort.

In a nationwide Finnish cohort of 1,502 patients with atrial fibrillation and prior intracranial bleeding, the 1-year risk of ischemic stroke fell from 4.1% with no anticoagulation to 0.7% with DOACs (HR 0.17), without an increased bleeding risk. Warfarin also reduced stroke and mortality rates but carried a higher bleeding risk (HR 1.85), which was mitigated when time in therapeutic range reached ≥70%. These findings support DOACs as a preferred anticoagulant in this high-risk population and underscore the need for individualized risk-benefit assessment.

## Abstract (original, from the publication)

BACKGROUND AND OBJECTIVES: Patients with atrial fibrillation (AF) and previous intracranial bleeding are at high risk of ischemic and bleeding events, and the benefits and risks of oral anticoagulation (OAC) remain uncertain. We investigated competing risks of recurrent intracranial bleeding, ischemic stroke (IS), and death from other causes according to anticoagulation strategy. METHODS: This nationwide Finnish cohort study using linked administrative registries included patients with first-ever AF diagnosed in 2010-2018 and intracranial bleeding at least 120 days earlier. Follow-up began 90 days after AF diagnosis. Patients were categorized as receiving direct oral anticoagulants (DOACs), warfarin, or no OAC based on drug purchases. Warfarin users were further stratified by time in therapeutic range (TTR). Inverse probability of treatment weighting balanced baseline characteristics. Competing risks were analyzed using adjusted cumulative incidence functions and cause-specific Cox regression. RESULTS: Among 1,502 patients (median age 78 years [IQR 71-85], 44% female, 41% with only traumatic intracranial bleeding), 15% received DOACs, 29% warfarin, and 56% no OAC. At 1 year, adjusted absolute risks of IS were 0.7%, 2.1%, and 4.1%; intracranial bleeding, 1.2%, 2.7%, and 1.9%; and death from other causes, 4.7%, 8.6%, and 14.7%, respectively. Compared with no OAC, DOAC use was associated with lower risks of IS (HR 0.17, 95% CI 0.04-0.71) and death (HR 0.20, 95% CI 0.09-0.46) without increased intracranial bleeding risk (HR 0.70, 95% CI 0.19-2.50). Warfarin use was associated with lower risks of IS (HR 0.49, 95% CI 0.26-0.93) and death (HR 0.60, 95% CI 0.44-0.80), but increased intracranial bleeding risk (HR 1.85, 95% CI 1.01-3.41). Among warfarin users, TTR ≥70% was associated with lower risks of IS (HR 0.24, 95% CI 0.08-0.79) and death (HR 0.19, 95% CI 0.10-0.36); associations were attenuated with poorer or missing TTR. DISCUSSION: In patients with AF and previous intracranial bleeding, OAC was associated with lower risks of IS and death. DOAC use was not associated with increased intracranial bleeding risk, whereas warfarin use was. Limited information on previous intracranial bleeding and potential residual confounding warrant cautious interpretation. These findings support individualized anticoagulation decisions in this high-risk population.

Auteurs: Paula Tiili, Mika Lehto, Olli Halminen, Ossi Lehtonen, Jari Haukka, Miika Linna, Jarno Satopää, Miikka Korja, Mika Niemelä, Janne Kinnunen, Aapo Aro, Pirjo Mustonen, Juha E K Hartikainen, Juhani K E Airaksinen, Jukka Putaala

---
Bron: Neurology, https://doi.org/10.1212/WNL.0000000000218719. Bijgewerkt 2026-10-24T00:58:48Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.